Skip to main content

Protara Therapeutics, Inc.

TARA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001359931

No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Protara Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of TARA: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders5040−10
Shares8.53M7.11M−1.42M (−16.6%)
Value$134.0M$69.3M−$64.8M (−48.3%)

New holders (9)

Institutions that held Protara Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to TARA in Q2 2021
InstitutionSharesValue% of portfolio
Goldman Sachs Group Inc132,257$1.29M0.00%
Two Sigma Investments, LP55,405$540.0K0.00%
Susquehanna International Group, LLP20,609$201.0K0.00%
Ergoteles LLC17,700$172.0K0.00%
Jane Street Group, LLC13,678$133.0K0.00%
HRT Financial LP12,151$118.0K0.00%
Prelude Capital Management, LLC11,700$114.0K0.01%
Simplex Trading, LLC581$5.00K0.00%
Retirement Group, LLC500$5.00K0.00%

Sold out (19)

Institutions that held Protara Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.